Table 2.

Summary of pharmacokinetic parameters for onartuzumab in cynomolgus monkeys and projected pharmacokinetic parameters in humans with nonlinear two-compartment model analysis

Projected pharmacokinetic parameters for humans
Observed for cynomolgus monkeysScaling exponent for CL
0.90.850.75
Estimate(% RSE)Estimate(% RSE)Estimate(% RSE)Estimate(% RSE)
Vmax (μg/d/kg)152(51.4)107(64.8)90.3(14.0)63.8(4.40)
Km (μg/mL)4.89(56.9)4.80(43.1)4.75(36.4)4.66(0.670)
CLL (mL/d/kg)9.81(15.7)7.16(53.5)6.12(6.14)4.46(5.54)
V1 (mL/kg)36.9(2.93)36.9(20.8)36.9(2.79)36.9(0.854)
CLd (mL/d/kg)39.8(11.6)28.8(12)24.6(11.7)17.8(13.3)
V2 (mL/kg)50.8(6.16)50.6(17.9)50.5(8.32)50.4(0.685)

RSE = relative SE.